Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer

Huber Rudolf M., Reck Martin, Thomas Michael

Source: Eur Respir J 2013; 42: 1119-1133

Journal Issue: October

Disease area: Thoracic oncology

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Huber Rudolf M., Reck Martin, Thomas Michael. Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer. Eur Respir J 2013; 42: 1119-1133

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Interdisciplinary multimodality management of stage III nonsmall cell lung cancer Source: Eur Respir Rev, 28 (152) 190024; 10.1183/16000617.0024-2019 Year: 2019
Current neoadjuvant/adjuvant treatment for advanced stage lung cancer Source: International Congress 2014 – PG19 Surgery for advanced stage lung cancer Year: 2014
The treatment of stage IV non-small cell lung cancer with target therapies Source: Annual Congress 2013 –Which treatment other than chemotherapy for stage IV NSCLC? Year: 2013
Surgical multimodality treatment for stage III non-small cell lung cancer (NSCLC) Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006
The method of individualisation of treatment and prognosis for advanced non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010
New treatment concepts in stage IV non-small cell lung cancer: personalised multidisciplinary approaches Source: Virtual Congress 2021 – Thoracic oncology Year: 2021
Multimodality management of non-small cell lung cancer stage III: the pulmonologist as pilot and partner Source: Virtual Congress 2021 – Thoracic oncology Year: 2021
The correlation between clinical and pathomorphological impacts of induction chemotherapy and long-term results of multimodality treatment for IIIA stage non-small cell lung cancer Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
Radiotherapy with curative intent for stage I and II non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight Source: ERS webinar 2021: Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight Year: 2021
First- and second-line therapy for advanced nonsmall cell lung cancer Source: Eur Respir J 2009; 33: 915-930 Year: 2009
Management of locally advanced nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 260–270 Year: 2009
Current challenges in the management of nonsmall cell lung cancer brain metastases Source: Eur Respir J, 55 (1) 1901686; 10.1183/13993003.01686-2019 Year: 2020
The optimal treatment of stage I nonsmall cell lung cancer in the era of SABR and modern day lung resections Source: Eur Respir J, 56 (5) 2002595; 10.1183/13993003.02595-2020 Year: 2020
Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives Source: Eur Respir Rev 2011; 20: 45-52 Year: 2011
Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer Source: Annual Congress 2011 - General thoracic surgery II Year: 2011
Staging and restaging in the era of multimodality treatment Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006